Pomalidomide plus low-dose dexamethasone (POM + LoDEX) versus high-dose dexamethasone (HiDEX) in relapsed/refractory multiple myeloma (RRMM): MM-003 analysis of patients (pts) with moderate renal impairment (RI).
Katja C. Weisel
Consultant or Advisory Role - Celgene
Honoraria - Celgene
Meletios A. Dimopoulos
Consultant or Advisory Role - Celgene; Ortho Biotech
Honoraria - Celgene
Research Funding - Genesis Pharmaceuticals
Philippe Moreau
Consultant or Advisory Role - Celgene; Janssen; Millennium
Honoraria - Celgene; Janssen; Millennium
Martha Lacy
Research Funding - Celgene
Kevin W. Song
Consultant or Advisory Role - Celgene; Janssen
Honoraria - Celgene; Janssen
Research Funding - Celgene; Janssen
Michel Delforge
Consultant or Advisory Role - Celgene; Janssen
Honoraria - Celgene; Janssen
Lionel Karlin
Consultant or Advisory Role - Celgene
Honoraria - Celgene; Janssen
Expert Testimony - Celgene
Other Remuneration - Celgene; Janssen
Hartmut Goldschmidt
Consultant or Advisory Role - Celgene
Honoraria - Celgene
Research Funding - Celgene
Anne Banos
No relevant relationships to disclose
Albert Oriol Rocafiguera
Consultant or Advisory Role - Celgene
Honoraria - Celgene
Xin Yu
Employment or Leadership Position - Celgene
Lars Sternas
Employment or Leadership Position - Celgene
Stock Ownership - Celgene
Christian Jacques
Employment or Leadership Position - Celgene
Stock Ownership - Celgene
Mohamed H. Zaki
Research Funding - Celgene
Jesùs F. San-Miguel
Consultant or Advisory Role - Celgene; Janssen; Millennium; Novartis; Onyx
Honoraria - Celgene; Janssen; Millennium; Novartis; Onyx